Ario Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ario Pharma - overview
Location
Cambridge, England, UK
Primary Industry
Pharmaceuticals
About
Ario Pharma is a UK-based company specializing in the pharmaceutical sector, focusing on providing a premium digital domain for businesses in the biotechnology and healthcare industries. Ario Pharma operates as a digital platform within the pharmaceutical and biotechnology sectors, offering its domain name as a valuable asset for online presence. Founded in Cambridge, UK, the company received investment from Forbion Capital Partners, New Science Ventures, and Seroba Life Sciences in a Series A funding round on September 23, 2013, raising GBP 1. 9 million and achieving a post-money valuation of GBP 11.
87 million. The company has completed 2 deals to date. ArioPharma. com offers its specialized domain name as a premium asset in the pharmaceutical and biotechnology sectors.
This platform serves businesses and individuals aiming to enhance their online presence, targeting clients involved in drug development, healthcare solutions, and pharmaceutical marketing across North America, Europe, and Asia. The revenue model for ArioPharma. com is centered around domain sales and leasing, with a purchase price of USD 2,695 or a monthly payment option of USD 112. 29 over 24 months.
Clients, including startups and established pharmaceutical companies, engage directly with the company for either outright purchases or financing arrangements, ensuring accessibility to digital branding solutions. Ario Pharma plans to leverage recent funding from the Series A round to expand its services and enhance its digital platform. The investment will be directed towards improving domain offerings and exploring additional markets for growth. The company aims to solidify its presence in the pharmaceutical sector while also potentially looking into healthcare technology solutions to broaden its market reach.
Current Investors
Seroba, Forbion, New Science Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.ariopharma.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Ario Pharma - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Ario Pharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.